HIV-1 infection
Infectious disease · 2007–2023
23decisions
16medicines
3carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lenacapavir Treatment of people with highly multi-drug resistant HIV-1 infection who have no more than 2 fully active antiretrovirals remaining from the 4 main classes… | Nov 2023 | Recommended with restriction | input received National Association of People · HIV Australia |
| cabotegravir and rilpivirine Treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL). Cabotegravir tablets are for oral lead-in to assess… | Mar 2021 | Not recommended | input received National Association for People Living · National Aboriginal Community Controlled Health Organisation |
| cabotegravir and rilpivirine Treatment of HIV-1 infection in virologically suppressed adults (HIV-1 RNA <50 copies/mL) who are switching therapy. Cabotegravir oral tablets serve as a… | Nov 2021 | Recommended with restriction | 1 individuals |
| dolutegravir with lamivudine Treatment of HIV-1 infection in adults and adolescents (from 12 years of age weighing at least 40kg), to replace the current antiretroviral regimen in those… | Jul 2020 | Recommended with restriction | none received |
| dolutegravir with lamivudine Treatment of HIV-1 infection in adult and adolescent patients (12 years and older). The submission requested listing for both treatment-naïve and… | Jul 2019 | Deferred | unclear |
| dolutegravir with lamivudine Treatment of HIV-1 infection in adult and adolescent patients (12 years and older, weighing ≥40kg). The submission requested listing for both treatment-naïve… | Jul 2019 | Deferred | unclear |
| tenofovir with emtricitabine and efavirenz; tenofovir with emtricitabine and rilpivirine; tenofovir with emtricitabine, elvitegravir and cobicistat Treatment of HIV infection in adults and adolescents. This submission concerns proposed revocation of listings and potential delisting from the PBS. | Mar 2019 | Noted | no section in document |
| bictegravir + emtricitabine + tenofovir alafenamide Treatment of human immunodeficiency virus (HIV-1) infection in treatment-naïve and virologically suppressed patients. | Mar 2018 | Deferred | none received |
| raltegravir Treatment of HIV-1 infection in antiretroviral treatment-naïve patients, treatment-experienced patients, and patients virologically suppressed on raltegravir… | Jul 2017 | Deferred | none received |
| tenofovir alafenamide / emtricitabine Treatment of HIV-1 infection in treatment-naïve and treatment-experienced patients as part of combination antiretroviral therapy. | Jul 2016 | Recommended with restriction | none received |
| darunavir + cobicistat Treatment of HIV-1 infection in combination with other antiretroviral agents in antiretroviral treatment-naïve patients and treatment-experienced patients with… | Mar 2016 | Recommended with restriction | none received |
| elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide Treatment of human immunodeficiency virus (HIV) infection in treatment-naïve patients and treatment-experienced patients with clinical indication to switch… | Nov 2015 | Recommended with restriction | none received |
| atazanavir/cobicistat Treatment of HIV-1 infection in combination with other antiretroviral agents in antiretroviral treatment-naive and treatment-experienced adults. | Nov 2015 | Recommended with restriction | none received |
| elvitegravir Continuing treatment of HIV-1 infection in antiretroviral treatment-experienced patients, in combination with a ritonavir-boosted protease inhibitor and other… | Mar 2013 | Not recommended | no section in document |
| maraviroc Treatment of adult patients with CCR5-tropic HIV-1 infection, including both treatment-naïve and treatment-experienced patients, in combination with other… | Nov 2012 | Deferred | no section in document |
| maraviroc First-line and continuing treatment of CCR5-tropic HIV-1 infection in combination with other antiretroviral agents in patients with CD4 count <500 cells/mm³ or… | Nov 2012 | Deferred | no section in document |
| raltegravir potassium Treatment of human immunodeficiency virus (HIV-1) infection in treatment-naïve adult patients in combination with other antiretroviral agents, for patients… | Mar 2010 | Recommended with restriction | no section in document |
| raltegravir potassium Treatment of HIV-1 infection in treatment-naïve patients in combination with other antiretroviral agents, with evidence of HIV replication (viral load >10,000… | Mar 2010 | Recommended with restriction | no section in document |
| etravirine Treatment of HIV-1 infection in combination with other antiretroviral agents in antiretroviral treatment-experienced adults with evidence of viral replication… | Mar 2009 | Recommended with restriction | no section in document |
| darunavir Treatment of HIV-1 infection in combination with other antiretroviral agents in antiretroviral experienced patients who have failed previous treatment with, or… | Nov 2009 | Recommended with restriction | no section in document |
| maraviroc Treatment of antiretroviral experienced patients infected with only CCR5-tropic HIV-1 with evidence of HIV replication (viral load greater than 5,000 copies… | Nov 2009 | Recommended with restriction | no section in document |
| maraviroc Treatment of antiretroviral-experienced adult patients infected with CCR5-tropic HIV-1, in combination with other antiretroviral agents. | Nov 2008 | Recommended | no section in document |
| darunavir ethanolate Treatment of HIV-1 infection in antiretroviral treatment experienced patients with evidence of viral replication and/or CD4 cell counts less than 500 per cubic… | Jul 2007 | Recommended with restriction | no section in document |
Who spoke
National Association for People Living · National Aboriginal Community Controlled Health Organisation · National Association of People · HIV Australia
What the PBS pays
$875M in government benefit over 2024–25, across 732,242 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| tenofovir disoproxil fumarate with emtricitabine and efavirenz; tenofovir disoproxil fumarate with emtricitabine and rilpivirine; tenofovir disoproxil fumarate with emtricitabine, elvitegravir and cobicistat | $192.4M |
| elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | $178.5M |
| bictegravir + emtricitabine + tenofovir alafenamide | $175.6M |
| tenofovir alafenamide / emtricitabine | $175.6M |
| dolutegravir with lamivudine | $57M |
| darunavir + cobicistat | $23.1M |
| cabotegravir and rilpivirine | $21.4M |
| atazanavir/cobicistat | $20.7M |
| elvitegravir | $13.7M |
| darunavir | $9.2M |
| raltegravir | $2.2M |
| raltegravir potassium | $2.2M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| nevirapineAPO-NEVIRAPINE nevirapine 200 mg tablet blister pack | 2000 | 12 |
| fostemsavir trometamolRUKOBIA fostemsavir (as trometamol) 600 mg extended release tablet bot | 2021 | 1 |
| doravirinePIFELTRO doravirine 100 mg film-coated tablet bottle | 2019 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 13 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.